Elizabeth Thompson, PhD at Horizon Therapeutics shares details about Tepezza for treating thyroid eye disease (TED), a rare autoimmune disease causing permanent facial disfigurement severely affecting patients’ quality of life and daily function. The disease often presents suddenly, with an avalanche of endocrine and ophthalmic symptoms impairing normal life.

TED is most often associated with Graves’ disease (GD), but also can occur in association with hypothyroidism, euthyroidism, and Hashimoto’s thyroiditis. GD affects approximately 1% to 2% of the adult population, with an estimated 40% of GD patients subsequently developing TED over the course of their lifetime. The onset of TED typically occurs between 30 and 50 years of age, with the disease course more severe after age 50.

In January, 2020, the U.S. Food and Drug Administration (FDA) approved Horizon’s Tepezza (teprotumumab trbw), the first drug indicated to treat thyroid eye disease. Tepezza inhibits (or blocks) the activity of the protein insulin-like growth factor-1, which is believed to a play as significant role in the development of the disorder. Affected individuals have shown significant improvement in proptosis, double vision, and overall quality of life when taking Tepezza.

For more information about TED and other rare eye disorders, visit https://checkrare.com/diseases/ophthalmology-eye-diseases/.